CRIS Current Research Information System

BARBATO, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.198
NA - Nord America 1.475
EU - Europa 903
SA - Sud America 158
Continente sconosciuto - Info sul continente non disponibili 97
AF - Africa 94
OC - Oceania 7
Totale 4.932
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.405
VN - Vietnam 947
SG - Singapore 416
CN - Cina 413
IT - Italia 401
HK - Hong Kong 120
BR - Brasile 109
DE - Germania 91
GB - Regno Unito 81
BD - Bangladesh 75
FR - Francia 64
KR - Corea 64
IN - India 52
SE - Svezia 51
NL - Olanda 49
FI - Finlandia 41
CI - Costa d'Avorio 31
CA - Canada 30
IE - Irlanda 28
JP - Giappone 28
RU - Federazione Russa 26
SC - Seychelles 20
ZA - Sudafrica 19
AR - Argentina 18
TG - Togo 12
AT - Austria 11
PL - Polonia 11
ES - Italia 10
IQ - Iraq 9
MX - Messico 9
TW - Taiwan 9
PH - Filippine 8
TH - Thailandia 8
CO - Colombia 7
EC - Ecuador 7
JO - Giordania 7
AU - Australia 6
BG - Bulgaria 6
ID - Indonesia 6
JM - Giamaica 6
CR - Costa Rica 5
CZ - Repubblica Ceca 5
EE - Estonia 5
MY - Malesia 5
SA - Arabia Saudita 5
TR - Turchia 5
UZ - Uzbekistan 5
CL - Cile 4
HR - Croazia 4
UA - Ucraina 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
BS - Bahamas 3
CH - Svizzera 3
IL - Israele 3
NI - Nicaragua 3
PK - Pakistan 3
PY - Paraguay 3
SV - El Salvador 3
UY - Uruguay 3
EG - Egitto 2
GH - Ghana 2
GR - Grecia 2
GT - Guatemala 2
HN - Honduras 2
KE - Kenya 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
PE - Perù 2
RO - Romania 2
RS - Serbia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AL - Albania 1
BB - Barbados 1
BO - Bolivia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GP - Guadalupe 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
MT - Malta 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
ZM - Zambia 1
Totale 4.836
Salva come PNG Salva come JPEG
Città #
Singapore 294
Ho Chi Minh City 285
Hanoi 232
Ashburn 170
Bologna 154
Hefei 120
San Jose 118
Hong Kong 112
Chandler 102
Dallas 92
Fairfield 64
Seoul 55
Council Bluffs 53
Santa Clara 53
Southend 45
New York 42
Haiphong 41
Lauterbourg 36
Beijing 32
Abidjan 31
Los Angeles 26
São Paulo 25
Dublin 24
Milan 22
Princeton 22
Tokyo 21
Boardman 20
Houston 20
Seattle 20
Wilmington 20
Redmond 19
Lappeenranta 18
Rome 18
Woodbridge 18
Cambridge 17
Helsinki 17
Da Nang 16
Biên Hòa 15
Dongguan 15
Quận Bình Thạnh 14
Chicago 13
Johannesburg 13
Phoenix 13
Shenzhen 13
Ann Arbor 12
Ha Long 12
Lomé 12
Ninh Bình 12
Thái Nguyên 12
Amsterdam 11
Bengaluru 11
Buffalo 11
Atlanta 10
Frankfurt am Main 10
Guangzhou 10
Munich 10
Redondo Beach 10
Điện Bàn 10
Can Tho 9
Hyderabad 9
Quận Một 9
Nanjing 8
Shanghai 8
Vũng Tàu 8
Amman 7
Bắc Giang 7
Bắc Ninh 7
Hải Dương 7
Madrid 7
Mexico City 7
San Francisco 7
Turin 7
Brooklyn 6
Bến Tre 6
Fabriano 6
Orem 6
Quận Phú Nhuận 6
Sofia 6
Turku 6
Vienna 6
Vinh 6
Warsaw 6
Bremen 5
Falkenstein 5
Florence 5
Jakarta 5
Montreal 5
Naples 5
North Charleston 5
Nuremberg 5
Paris 5
Quảng Ngãi 5
Rio de Janeiro 5
Stockholm 5
Wuhan 5
Ankara 4
Berlin 4
Bettystown 4
Brescia 4
Cernusco sul Naviglio 4
Totale 2.975
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 725
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 246
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 225
Hypoxia Decreases ROS level in human fibroblasts 219
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 219
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 218
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 198
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 195
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 179
The inhibitor protein (IF1) of the F1F0-ATPase modulates human osteosarcoma cell bioenergetics 166
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 148
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 135
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 131
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 128
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 127
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients 127
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma 125
null 125
The role of the ATPase inhibitor factor 1 (IF(1)) in cancer cells adaptation to hypoxia and anoxia 124
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 120
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 114
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS 106
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 104
How I Treat High-risk Multiple Myeloma 100
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 99
MicroRNAs in Oncogenesis and Tumor Suppression 97
null 96
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 95
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 90
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 86
Correction: Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 65
Totale 4.932
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.102
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.102
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022239 0 0 10 14 17 7 3 18 19 33 75 43
2022/2023330 42 46 6 52 14 31 11 16 67 10 25 10
2023/2024131 10 17 6 7 8 20 9 38 2 4 5 5
2024/2025620 26 27 52 60 57 18 41 15 25 68 75 156
2025/20262.916 299 646 195 211 195 161 223 100 459 177 138 112
2026/2027322 90 99 133 0 0 0 0 0 0 0 0 0
Totale 4.932